Tissue Biomarkers Predicting Lymph Node Status in Cutaneous Melanoma

Area of Science:

• Oncology
• Pathology
• Biomarker Research

Background:

• Cutaneous melanoma is an aggressive cancer with high risks of lymph node metastasis, distant spread, and recurrence.
• Accurate prediction of lymph node involvement is crucial for treatment decisions, particularly in cases currently deemed low-risk.
• Sentinel lymph node (SLN) biopsy is a key diagnostic tool, but its necessity in all cases is debated.

Purpose of the Study:

• To conduct a narrative literature review on tissue biomarkers for predicting lymph node invasiveness in cutaneous melanoma.
• To evaluate the utility of specific biomarkers, including vascular endothelium growth factors (VEGF), Tetraspanin CD9, LYVE-1, D2-40, and 31-GEP.
• To identify biomarkers that can refine risk stratification for SLN involvement.

Main Methods:

• Literature search for studies on tissue biomarkers and lymph node status in cutaneous melanoma.
• Review and synthesis of findings on VEGF, CD9, LYVE-1, D2-40, and 31-GEP.
• Analysis of biomarker performance in predicting SLN status and lymphovascular invasion.

Main Results:

• The 31-gene expression profile test (31-GEP) shows potential in distinguishing between low and high risk for positive SLN.
• VEGF receptor-3 and CD9 expression may serve as independent predictors of SLN positivity.
• LYVE-1 and D2-40 facilitate assessment of lymphovascular invasion, a predictor of SLN status.

Conclusions:

• Tissue biomarkers can aid clinicians in determining the need for SLN biopsy in cutaneous melanoma patients.
• Specific biomarkers like 31-GEP, VEGF receptor-3, CD9, LYVE-1, and D2-40 offer valuable prognostic information.
• Further research into these biomarkers may improve risk stratification and personalize treatment strategies for melanoma.